Vetter wins two coveted awards
Leading CDMO is granted both the WorldStar Award for Vetter-Ject and a 2016 CMO Leadership Award.
The World Packaging Organization (WPO) has awarded Vetter the WorldStar Award 2016 for its syringe closure system Vetter-Ject. The WorldStar competition is one of the major events of the WPO, and its award represents the pre-eminent international award in packaging. Vetter has now won four internationally recognized awards for a product only released in July 2015. Two of the awards, won prior to the products launch, include the IF Design Award, and the Red Dot Design Award. Recently, Vetter-Ject won the “German Packaging Award 2015”. At the same time, Vetter is proud to have also been awarded a CMO Leadership Award 2016 in four categories.
The WorldStar competition is open to any pack or packaging material that has won a recognized or domestic international award related to packaging in either 2014 or 2015. Winning of the German Packaging Award 2015 assured Vetter’s submission to the WorldStar competition. Representatives from 19 packaging associations judged 293 projects entered into the competition from 35 countries. The judging session took place over 2 days in October, 2015 as part of the 95th WPO Board Meeting activities. Vetter had previously won the WorldStar award in 1998 for the Vetter Lyo-Ject dual chamber syringe.
“The winning of this award, certainly one of the most prestigious in the field of global packaging, is very gratifying to Vetter, and yet another affirmation of the value that Vetter-Ject brings to the biopharmaceutical industry,” said Dr Claus Feussner, Senior Vice President, Vetter Development Service. “The three awards we had already received, combined with the WorldStar Award, are a validation of the novel design and technological advances of Vetter-Ject.” Since its introduction in July, Vetter has had positive feedback both from the market and our customers about this system.
Vetter-Ject offers more options for filling highly sensitive compoundsPharmaceutical and biotech companies are increasingly developing drugs that incorporate sensitive and complex compounds. Administering these drugs requires an injection system that can be used flexibly while being safe and simple to handle. Vetter-Ject is such a system, consisting of a needle hub and a needle shield. Due to the baked-in siliconization process for the glass barrel, less silicon oil than commonly used is necessary, making Vetter-Ject particularly suitable for silicone-sensitive drug products. The silicon content of the syringe can also be adjusted according to the requirements of the customer. Thus, the amount of silicon used; as well as the related particle load, can be reduced by up to 80% when compared to the standard siliconization process applied to conventional syringe systems.
Vetter-Ject is ready-to-use with an integrated needle that is simple to handle and user-friendly. The tamper-evident closure enables that any attempt at opening of the closure system will be immediately and permanently visible to the naked eye. Vetter-Ject®can be used with a wide range of primary packaging options like different stoppers and glass barrels, which can be customized according to the needs of the drug product.
Vetter is a winner of a 2016 CMO Leadership Award in four categoriesThe efficient vetting of potential CMO partners is a difficult experience for pharmaceutical and biopharmaceutical executives. To assist in this process, Life Science Leader magazine created the CMO Leadership Awards. More than 80 contract manufactures were assessed by 26 performance metrics in Industry Standard Research’s (ISR) annual Contract Manufacturing Quality Benchmarking survey. For 2016, Vetter was named the winner in four categories including, quality, capabilities, expertise, and compatibility.
“Vetter is pleased to be a recipient of this award, particularly since it is a direct reflection of our customers’ experience in having worked right alongside us,” said Peter Soelkner, Managing Director. “Their nomination and the granting of the award is a clear indication to Vetter that we continue to exceed the expectations of our peers in areas of critical importance to their business.
Unlike other industry awards that are based on a subjective voting or nomination process, only votes from companies that have cooperated on an outsourced project within the past 18 months in using CMO services are counted.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance